Home
→
Browsing by Author

Browsing by Author "Clotet, Bonaventura"

Now showing items 21-38 of 38

Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery

Massanella, Marta; Gómez-Mora, Elisabet; Carrillo, Jorge; Curriu, Marta; Ouchi, Dan; Puig, Jordi; Negredo, Eugenia; Cabrera, Cecilia; Clotet, Bonaventura; Blanco, Julià (Biomed central, 2015)

Abstract Background: High levels of ex vivo CD4 T-cell death and the accumulation of highly differentiated and/or immunosenescent T cells have been associated with poor CD4 T-cell recovery in treated HIV-infected ...
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice

Santos, José R.; Llibre, Josep M.; Berrio-Galan, Daniel; Bravo, Isabel; Miranda, Cristina; Pérez-Alvarez, Susana; Pérez Alvarez, Núria; Paredes, Roger; Clotet, Bonaventura; Moltó, José (Oxford University Press, 2015)

Background: Data on the efficacy of simplifying therapy using darunavir/ritonavir and lopinavir/ritonavir monotherapy in clinical practice remain limited. Methods: A retrospective single-centre study including patients ...
A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques

Mothe, B.; Hu, Xintao; Llano, Anuska; Rosati, Margherita; Olvera, Alex; Kulkarni, Viraj; Valentin, Antonio; Alicea, Candido; Sardesai, Niranjan J.; Rocafort, Muntsa; Crespo, Manel; Carrillo, Jorge; Marco, Andrés; Mullins, James I.; Dorrell, Lucy; Hanke, Thomas; Clotet, Bonaventura; Pavlakis, George N.; Felber, Barbara; Brander, Christian (Mary Ann Liebert, Inc, 2014)
Oral human papillomavirus type-specific infection in HIV-infected men: a prospective cohort study among men who have sex with men and heterosexual men.

Darwich, L.; Cañadas, M.P.; Videla, S.; Coll, J.; Molina-López, R.A.; Cobarsi, P.; Sirera, Guillem; Clotet, Bonaventura (Wiley, 2014)

The natural history of type-specific oral infection of human papillomavirus (HPV) was assessed in a cohort of HIV-infected men (538 men who have sex with men (MSM); 195 heterosexuals). Risk factors associated with oral ...
Perfil de resistencias y barrera genética de dolutegravir

Llibre, Josep M.; Clotet, Bonaventura (Elsevier, 2015)

Dolutegravir tiene un perfil de resistencias significativamente distinto al de anteriores inhibidores de la integrasa. Es activo in vitro frente a VIH-1 (virus de la inmunodeficiencia humana-1) portador de cualquier mutación ...
Plasma HIV-1 Tropism and the Risk of Short- Term Clinical Progression to AIDS or Death

Casadellà, Maria; Cozzi-Lepri, Alessandro; Phillips, Andrew; Noguera-Julian, Marc; Bickel, Markus; Sedlacek, Dalibor; Zilmer, Kai; Clotet, Bonaventura; Lundgren, Jens D.; Paredes, Roger (Plos One, 2017)

Objective To investigate if plasma HIV-1 tropism testing could identify subjects at higher risk for clinical progression and death in routine clinical management. Design Nested case-control study within the EuroSIDA ...
Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner

Guardiola, M.; Echeverria, Patricia; González, Marta; Vallvé, Joan Carles; Puig, Jordi; Clotet, Bonaventura; Ribalta, J.; Negredo, Eugenia (Mary Ann Liebert, 2015)

Introduction: HIV-infected patients treated with Highly Active Antiretroviral Therapy (HAART) may be predisposed to hypertriglyceridemia, which gives rise to a highly atherogenic lipid profile known as atherogenic ...
Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients

Echeverria, Patricia; Domingo, Pere; Llibre, Josep M.; Gutierrez, Mar; Mateo, Gracia; Puig, Jordi; Bonjoch, Anna; Pérez Alvarez, Núria; Sirera, Guillem; Clotet, Bonaventura; Negredo, Eugenia (Hindawi Publishing Corporation, 2014)

There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable cardiovascular risk factors (CVRF) inHIV-infected patients. Methods.We performed a retrospective descriptive ...
Primary resistance to integrase strand-transfer inhibitors in Europe

Casadellà, Maria; Van Ham, P.M.; Noguera-Julian, Marc; Van Kessel, A.; Pou, Christian; Hofstra, L.M.; Santos, José R.; Garcia, Federico; Struck, D.; Alexiev, I.; Bakken Kran, A.M.; Hoepelman, A.I.; Kostrikis, L.G.; Somogyi, S.; Liitsola, K.; Linka, M.; Nielsen, C.; Otelea, D.; Paraskevis, D.; Poljak, M.; Puchhammer-Stöckl, E.; Staneková, D.; Stanojevic, M.; Van Laethem, K.; Zidovec Lepej, S.; Clotet, Bonaventura; Boucher, C.A.B.; Paredes, Roger; Wensing, A.M.J. (Oxford University Press, 2015)

Objectives: The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance. Methods: ...
Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif

Molinos-Albert, Luis M.; Bilbao, Eneritz; Agulló, Luis; Marfil, Sílvia; García, Elisabet; Rodríguez de la Concepción, Maria L.; Izquierdo Useros, Nuria; Vilaplana, Cristina; Nieto-Garai, Jon A.; Contreras, F. Xabier; Floor, Martin; Cardona, Pere J.; Martinez Picado, Francisco Javier; Clotet, Bonaventura; Villà-Freixa, Jordi; Lorizate, M.; Carrillo, Jorge; Blanco, Julià (Nature Publishing Group, 2017)

The HIV-1 gp41 Membrane Proximal External Region (MPER) is recognized by broadly neutralizing antibodies and represents a promising vaccine target. However, MPER immunogenicity and antibody activity are influenced by ...
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (International AIDS Society, 2014)

Abstract INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1-3] It ...
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial

Moltó, José; Valle, Marta; Ferrer, Elena; Domingo, Pere; Curran, Adrian; Santos, José R.; Di Yacovo, María Silvana; Miranda, Cristina; Podzamczer Palter, Daniel; Clotet, Bonaventura (Oxford University Press, 2015)

Objectives: Maximizing ART efficiency is of growing interest. This study assessed the efficacy, safety, pharmacokinetics and economics of a darunavir dose-reduction strategy. Methods: This was a multicentre, randomized, ...
Safety and immunogenicity of a modified vaccinia ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1

Mothe, B.; Climent, Núria; Plana, Montserrat; Rosas, Miriam; Jiménez, José Luis; Muñoz Fernández, María Ángeles; Puertas, M.C.; Carrillo, Jorge; Gonzalez, Nuria; Leon, Agathe; Pich, Judit; Arnaiz, Joan Albert; Gatell, J.M.; Clotet, Bonaventura; Blanco, Julià; Alcamí, José; Martinez Picado, Francisco Javier; Alvarez Fernández, Carmen; Sánchez Palomino, Sonsoles; Guardo, Alberto C.; Peña, José; Benito, José M.; Rallón, Norma; Gómez, Carmen E.; Perdiguero, Beatriz; García Arriaza, Juan; Esteban, Mariano; López Bernaldo de Quirós, Juan Carlos; Brander, Christian; Garcia, Felipe (Oxford University Press, 2015)

Objectives: The safety, immunogenicity, impact on the latent reservoir and rebound of viral load after therapeutic HIV-1 vaccination with recombinant modified vaccinia Ankara-based (MVA-B) HIV-1 vaccine expressing ...
Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1-infected patients

De Arquer, Guillermo Robert; Peña, Ruth; Cabrera, Cecilia; Coma, Gemma; Ruiz Hernández, Raul; Guerola, Rosa; Clotet, Bonaventura; Ruiz, Lídia; Esté, José A.; Calle, M. Luz; Bofill, Margarita (Society for Leukocyte Biology, 2007)

IL-12 and IL-18 synergistically induce the production of IFN- by resting and activated T cells. To evaluate whether this induction was affected in HIV-1-infected patients, PBMC or isolated CD4 T cells were cultured ...
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels

Negredo, Eugenia; Diez-Pérez, Adolfo; Bonjoch, Anna; Domingo, Pere; Pérez Alvarez, Núria; Gutierrez, Mar; Mateo, Gracia; Puig, Jordi; Echeverria, Patricia; Escrig, R.; Clotet, Bonaventura (Oxford University Press, 2015)

Background: Tenofovir is involved in accelerated bone mineral density (BMD) loss. Methods: We recently published a hip BMD improvement at week 48 [+2.1% (95% CI: 20.6, 4.7) (P¼0.043)] in HIV-infected patients with ...
Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients

Negredo, Eugenia; Puig, Jordi; Ornelas, Arelly; Echeverria, Patricia; Bonjoch, Anna; Estany, Carla; Higueras, Carmen; Gonzalez-Mestre, Vicente; Clotet, Bonaventura (Mary Ann Liebert, 2015)

Long-term results ( > 5 years) for synthetic substances used to repair facial lipoatrophy have not been published. We performed a cross-sectional study to evaluate the 10-year safety of polyacrylamide hydrogel (Aquamid) among ...
The Lipid-Lowering Effect of Tenofovir/ Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Llibre, Josep M.; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (Oxford University Press, 2015)

Background. It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipidneutral emtricitabine (FTC), has a lipid-lowering effect. Methods. We performed a randomized, crossover, ...
Virological failure to raltegravir in spain: Incidence, prevalence and clinical consequences

Santos, José R.; Blanco, José Luis; Masiá, Mar; Gutiérrez, Félix; Pérez-Elías, María Jesús; Iribarren, José Antonio; Force, Lluis; Antela, Antonio; Knobel, Hernando; Salavert, Miquel; López Bernaldo de Quirós, Juan Carlos; Pino, Maria; Paredes, Roger; Clotet, Bonaventura (Oxford University Press, 2015)

Objectives: The objective of this study was to evaluate the incidence, prevalence and clinical consequences of virological failure (VF) to raltegravir-based regimens in Spain. Methods: A multicentre, retrospective, ...

Now showing items 21-38 of 38

Search RIUVic

Advanced Search

Browse

All of DSpace

Browsing by Author "Clotet, Bonaventura"

Browsing by Author "Clotet, Bonaventura"

Search RIUVic

Browse

All of DSpace